Abstract
Aicardi Goutieres Syndrome (AGS) is characterized by mutations occurring in genes encoding RNAses. AGS mutations silence intracellular RNases resulting in an intracellular overload of short RNAs arresting the physiological production of microRNA required for brain development. MiR-219 is typically down-regulated in Aicardi Goutieres Syn-drome (AGS). The goal of this study is to investigate miR-219 role in protecting astrocytes co-cultured with AGS-mutated lymphocytes. These lymphocytes display neurotoxic properties due to the presence of AGS-mutation and to their activa-tion by interpheron-alpha (IFN). Obtained results provide the evidence that astrocytes transfected with microRNA-219 are protected from the neurotoxic action of AGS lymphocytes activated by IFN-alpha. In particular, the miR-219 transfection increased astrocyte viability, growth, and differentiation while decreasing cell necrosis and apoptosis. Thus, microRNA-219 transfection is a valuable strategy in order to confer resistance to astrocytes towards lymphocyte-induced neurotoxici-ty especially in the presence of IFN-alpha, whose levels are typically increased in the cerebrospinal fluid of AGS patients.
Keywords: Aicardi Goutieres Syndrome, interferon-alpha, lymphocytes, microRNA, miR-219 transfection, neurotoxicity.
MicroRNA
Title:Prevention of Lymphocyte Neurotoxic Effects by microRNA Delivery
Volume: 2 Issue: 3
Author(s): Alessandra Pulliero, Barbara Marengo, Daniela Fenoglio, Alessia Parodi, Cristina Cereda, Cinzia Domenicotti, Simona Orcesi, Jessica Galli, Ivana Olivieri, Gilberto Filaci, Umberto Balottin, Elisa Fazzi and Alberto Izzotti
Affiliation:
Keywords: Aicardi Goutieres Syndrome, interferon-alpha, lymphocytes, microRNA, miR-219 transfection, neurotoxicity.
Abstract: Aicardi Goutieres Syndrome (AGS) is characterized by mutations occurring in genes encoding RNAses. AGS mutations silence intracellular RNases resulting in an intracellular overload of short RNAs arresting the physiological production of microRNA required for brain development. MiR-219 is typically down-regulated in Aicardi Goutieres Syn-drome (AGS). The goal of this study is to investigate miR-219 role in protecting astrocytes co-cultured with AGS-mutated lymphocytes. These lymphocytes display neurotoxic properties due to the presence of AGS-mutation and to their activa-tion by interpheron-alpha (IFN). Obtained results provide the evidence that astrocytes transfected with microRNA-219 are protected from the neurotoxic action of AGS lymphocytes activated by IFN-alpha. In particular, the miR-219 transfection increased astrocyte viability, growth, and differentiation while decreasing cell necrosis and apoptosis. Thus, microRNA-219 transfection is a valuable strategy in order to confer resistance to astrocytes towards lymphocyte-induced neurotoxici-ty especially in the presence of IFN-alpha, whose levels are typically increased in the cerebrospinal fluid of AGS patients.
Export Options
About this article
Cite this article as:
Pulliero Alessandra, Marengo Barbara, Fenoglio Daniela, Parodi Alessia, Cereda Cristina, Domenicotti Cinzia, Orcesi Simona, Galli Jessica, Olivieri Ivana, Filaci Gilberto, Balottin Umberto, Fazzi Elisa and Izzotti Alberto, Prevention of Lymphocyte Neurotoxic Effects by microRNA Delivery, MicroRNA 2013; 2 (3) . https://dx.doi.org/10.2174/22115366113029990010
DOI https://dx.doi.org/10.2174/22115366113029990010 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimer's Disease and Chinese Medicine as a Useful Alternative Intervention Tool: A Mini-Review
Current Alzheimer Research The Medical Implications of Gastrointestinal Vagal Afferent Pathways in Nausea and Vomiting
Current Pharmaceutical Design Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain
Current Neuropharmacology Intravenous Application of Allogenic Peripheral Blood-Derived Mesenchymal Stem Cells: A Safety Assessment in 291 Equine Recipients
Current Stem Cell Research & Therapy Bridge Between Neuroimmunity and Traumatic Brain Injury
Current Pharmaceutical Design Adenosine Neuromodulation and Traumatic Brain Injury
Current Neuropharmacology Nanomedicine for Gene Delivery for the Treatment of Cardiovascular Diseases
Current Gene Therapy Stem Cell Therapy for Spinal Cord Injury
Current Medicinal Chemistry The Long Pentraxin PTX3, a Soluble Pattern Recognition Receptor Involved in Innate Immunity,Inflammation and Female Fertility
Current Immunology Reviews (Discontinued) Research Advancements in Porcine Derived Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Aquaporin Water Channels in Central Nervous System
Current Neurovascular Research Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Nanotechnology approaches for pain therapy through transdermal drug delivery
Current Pharmaceutical Design The Role of COX-2 in Acute Pain and the Use of Selective COX-2 Inhibitors for Acute Pain Relief
Current Pharmaceutical Design Differentiation Between Osteoporotic and Neoplastic Vertebral Fractures: State of The Art and Future Perspectives
Current Medical Imaging Cerebrospinal Fluid Flow Dynamics in Multiple Sclerosis Patients through Phase Contrast Magnetic Resonance Imaging
Current Neurovascular Research Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets An Overview of Current Applications of Nanotechnology in Biomedical Research: A Patent Survey
Recent Patents on Nanomedicine Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease
Current Pharmaceutical Design